| Literature DB >> 30365822 |
Janaína Campos Senra1, Mariana Azevedo Carvalho1, Agatha Sacramento Rodrigues1, Vera Lúcia Jornada Krebs2, Maria Augusta Bento Cicaroni Gibelli2, Rossana Pulcineli Vieira Francisco1, Lisandra Stein Bernardes1.
Abstract
Since studies show that an unfavorable environment during intrauterine development predisposes individuals to several diseases in adulthood, our objective is to assess the relation between fetal growth restriction and chronic renal disease in adults. We searched four different electronic databases through November 2017: CENTRAL, EMBASE, LILACS and MEDLINE. We selected studies with longitudinal or transversal designs associating kidney function in adulthood with low birth weight. Two reviewers evaluated the inclusion criteria and the risk of bias and extracted data from the included papers. Thirteen studies were selected for the systematic review and meta-analysis. We observed increased risks of presenting end-stage renal disease (risk ratio 1.31, 95% confidence interval: 1.17, 1.47), a lower glomerular filtration rate (ml/min) (mean difference 7.14; 95% confidence interval: -12.12, -2.16), microalbuminuria (risk ratio 1.40; 95% confidence interval: 1.28, 1.52) and a small increase in the albumin/creatinine ratio (mean difference 0.46; 95% confidence interval: 0.03, 0.90) in the low birth weight patients, compared with control group. These findings suggest that low birth weight is associated with renal dysfunction in adults.Entities:
Mesh:
Year: 2018 PMID: 30365822 PMCID: PMC6172979 DOI: 10.6061/clinics/2018/e401
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Figure 1Search flowchart.
Studies included in the meta-analysis.
| Author Year | Country | Design | Participants | Age, years | Predictor | No. of Participants | Outcomes | Frequency of Outcome/Value | OR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| Nelson et al. ( | United States | Prospective and retrospective cohort study | Pima Indians and closely related Tohono O'odham Indians with type 2 diabetes | 34±8 Range: 20 to 61 | LBW <2500 g | LBW: 16 Normal BW: 281 | Microalbuminuria: ACR≥30 mg/g | LBW: 10 Normal BW: 114 | Microalbuminuria: 1.54 [1.03, 2.31] |
| Hoy et al. ( | Australia | Cross-sectional study | Aborigines in the Australian Northern Territory | 27.1 Range: 20 to 38 | LBW (<2500 g) | LBW: 111 Normal BW: 206 | Albumin/ creatinine ratio (g/mol) | LBW: 3.1 (2.2-4.3) Normal BW: 2.2 (1.7-2.8) | ACR: 0.90 [-0.12, 1.92] |
| Kistner et al. ( | Sweden | Retrospective cohort study | Women born full term in Stockholm | 26±1.9 | (1) BW <2600 g and SGA (<25th percentile for gestational age) | (1): 18 (2): 17 | Glomerular filtration rate (clearance of iohexol) | (1): 100±14 ml/min/1.73 m2 (2): 107±14 ml/min/1.73 m2 | GFR (ml/min/1.73 m2): -7.00 [-16.28, 2.28] |
| Lackland ( | United States | Case-control study | Patients with chronic renal failure on dialysis from 1991 through 1996 | 34 | LBW (<2500 g) | LBW: 369 Normal BW: 2966 | End-stage renal disease | LBW: 147 Normal BW: 959 | ESRD: 1.23 [1.08, 1.41] |
| Vásárhelyi et al. ( | Hungary | Prospective cohort study | Healthy young Caucasian men | Range: 19 to 21 | LBW (<2500 g) | LBW: 49 Normal BW: 16 | Glomerular filtration rate (Schwartz formula) Albumin/ creatinine ratio (g/mol) | LBW: 127±22 ml/min Normal BW: 125±17 ml/min LBW: 0.91±2 g/mol Normal BW: 0.83±0.41 g/mol | GFR (ml/min): 2.00 [-8.36, 12.36] ACR: 0.08 [-0.58, 0.74] |
| Dyck et al. ( | Canada | Case-control study | Saskatchewan patients born after 1949 with ESRD diagnosed from 1981 through 1998 | - | LBW (≥2500 g) | LBW: 47 Normal BW: 748 | End-stage renal disease (dialysis or renal transplant) | LBW: 20 Normal BW: 235 | ESRD: 1.35 [0.96, 1.92] |
| Gielen et al. ( | Belgium | Cross-sectional study | Monozygotic and dizygotic twins | 25.6 | LBW (<2500 g) | LBW: 304 High BW: 349 | Glomerular filtration rate (creatinine clearance corrected for body surface area) | LBW: 93±28 ml/min High BW: 98±27 ml/min LBW: 93±24 ml/min/1.73 m2 High BW: 94±22 ml/min/1.73 m2 | GFR (ml/min): -5.00 [-9.23, -0.77] GFR (ml/min/1.73 m2): -1.00 [-4.55, 2.55] |
| Al Salmi et al. ( | Australia | Cross-sectional study | Ausdiab study population | ≥25 | LBW (<2500 g) | LBW: 42 Normal BW: 438 | Glomerular filtration rate (serum creatinine and lean body mass) | LBW: 74.9 ml/min (69.3-80.5) Normal BW: 84.4 ml/min (82.7-86.1) | GFR (ml/min): -9.50 (-15.19; -3.81) |
| Fan et al. ( | United States | Cross-sectional study | Caucasian and African American adults enrolled in the Medicaid program from 1993 to 1996 and diagnosed with diabetes or hypertension | Range: 18 to 50 Cases: 33.9±0.1 Controls: 37.6±0.6 | LBW (<2500 g) | LBW: 860 Normal BW: 6037 | End-stage renal disease | LBW: 27 Normal BW: 132 | ESRD: 1.44 [0.96, 2.16] |
| Al Salmi et al. ( | Australia | Case-control study | Patients attending the Nephrology Department during the first quarter of 2004 | Cases: 63.1±14.4 Controls: 62.7±16.6 | LBW (<2500 g) | LBW: 20 Normal BW: 193 | End-stage renal disease (GFR>15 ml/min/1.73 m2 or on dialysis therapy) | LBW: 13 Normal BW: 58 | ESRD: 2.16 [1.47, 3.18] |
| Li et al. ( | United States | Cross-sectional study | Patients with diabetes or hypertension or with a first-degree relative affected, registered in KEEP | 49.1±13.5 Range: 18 to 75 | LBW (<2500 g) | LBW: 1845 Normal BW: 9754 | Microalbuminuria: ACR≥30 mg/g | LBW: 481 Normal BW: 1840 | Microalbuminuria: 1.38 [1.27, 1.51] |
| Laganovic et al. ( | Croatia | Cross-sectional study | Healthy men | Cases: 21±0.89 Controls: 21.5±1.02 | SGA (<10th percentile for gestational age according to the Croatian population) | SGA: 95 AGA: 90 | Glomerular filtration rate (Cockcroft-Gault equation) Microalbuminuria: 2.2<ACR<22 mg/mmol Albumin/ creatinine ratio (g/mol) | SGA: 118.99±21.99 ml/min AGA: 131.88±23.02 ml/min SGA: 12 AGA: 4 SGA: 1.29±3.4 g/mol AGA: 0.59±0.8 g/mol | GFR (ml/min): -12.89 [-19.38, -6.40] Microalbuminuria: 2.84 [0.95, 8.49] ACR: 0.70 [-0.00, 1.40] |
| Ruggajo et al.( | Norway | Retrospective cohort study | Subjects registered in the Norwegian Renal Registry with ESRD or with a sibling who had ESRD or was SGA | Range: 18 to 42 | LBW (< the sex-specific 10th percentile) | LBW: 99170 Normal BW: 904964 | End-stage renal disease (dialysis or kidney transplantation) | LBW: 45 Normal BW: 306 | ESRD: 1.34 [0.98, 1.83] |
ACR, albumin/creatinine ratio; AGA, adequate for gestational age; BW, birth weight; ESRD, end-stage renal disease; GFR, glomerular filtration rate; LBW, low birth weight; SGA, small for gestational age.
Newcastle-Ottawa Quality Assessment Scale of the included studies (cohorts and case-controls).
| Study | Representativeness of the exposed cohort // Is the case definition adequate? | Selection of the non-exposed cohort // Representativeness of the cases | Ascertainment of exposure//Selection of controls | Demonstration that the outcome of interest was not present at the start of the study // Definition of controls | Comparability of (cohorts/cases and controls) based on the design or analysis | Assessment of (outcome/exposure) | Was the follow-up long enough for outcomes to occur? // Same method of ascertainment for cases and controls | Adequacy of the follow-up of cohorts // Non-response rate | Score |
|---|---|---|---|---|---|---|---|---|---|
| Nelson et al. ( | * | * | * | * | * | * | * | ||
| Kistner et al. ( | * | * | * | * | * | * | |||
| Lackland et al. ( | * | * | * | ** | * | * | |||
| Vásárhelyi et al. ( | * | * | * | * | * | ||||
| Dyck et al. ( | * | * | * | ** | * | * | |||
| Al Salmi et al. ( | * | * | * | * | |||||
| Ruggajo et al. ( | * | * | * | * | * |
Quality Assessment Tool for Cross-Sectional Studies included in the meta-analysis.
| Study | Research objective clearly stated? | Study population clearly defined? | Participation rate of eligible persons at least 50%? | All subjects recruited from similar populations? | Justification of the sample size? | Exposure measured prior to outcome? | Sufficient time frame to see an association between exposure and outcome? | Different levels of exposure measured? | Exposure measures clearly defined? | Exposure assessed more than once over time? | Outcome measures clearly defined? | Outcome assessors blinded to exposure status? | Loss to follow-up after baseline ≤20%? | Key potential confounders statistically adjusted for? | Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoy et al. ( | |||||||||||||||
| Gielen et al. ( | |||||||||||||||
| Al Salmi et al. ( | |||||||||||||||
| Fan et al. ( | |||||||||||||||
| Li et al. ( | |||||||||||||||
| Laganovic et al. ( |
CD, cannot determine; N, no; NR, not reported; Y, yes.
Figure 2Forest plot for end-stage renal disease (ESRD).
Figure 3Forest plot of glomerular filtration rate (ml/min).
Figure 4Forest plot of glomerular filtration rate (ml/min/1.73 m2).
Figure 5Forest plot of microalbuminuria.
Figure 6Forest plot of albumin/creatinine ratio (ACR).